Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 0.75 |
| ▸ | HTR1D | P28221 | 5/20 | 0.67 |
| ▸ | HTR1B | P28222 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733711 | 0.99 | MPO (0.97) | MPOHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL26508398 | 0.97 | MPO (0.94) | MPOHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL27836200 | 0.89 | MPO (1.00) | MPOHTR1AHTR1DHTR1BHTR7 | |
| SCHEMBL27836191 | 0.88 | MPO (0.78) | MPOHTR1AHTR1DHTR1BHTR7 | |
| SCHEMBL9541243 | 0.87 | MPO (0.76) | MPOHTR1AHTR7 | |
| SCHEMBL26508393 | 0.86 | MPO (0.75) | MPOHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL5170221 | 0.85 | MPO (0.77) | MPOHTR1AHTR2A | |
| SCHEMBL8557700 | 0.83 | MPO (0.71) | MPOHTR1AHTR2AHTR7 | |
| SCHEMBL8506914 | 0.83 | HTR1D (0.71) | MPOHTR1DHTR1BHTR2A | |
| SCHEMBL2933511 | 0.83 | HTR1A (0.75) | MPOHTR1AHTR1DHTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | UNIVERSITE LIBRE DE BEUXELLES (BE) | 2012-05-17 | — | — | US | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2023141595-A2 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | UNIVERSITE LIBRE DE BEUXELLES (BE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | UNIVERSITE LIBRE DE BEUXELLES (BE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | UNIVERSITE LIBRE DE BEUXELLES (BE) | 2012-05-17 | — | — | US | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | MPO 4308/4885HTR1A 746/4885HTR1D 1169/4885 |
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | MPO, SERPINB1, MAOA | MPO 1/4885HTR1A 37/4885HTR1D 177/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | MPO 896/4885HTR1A 5/4885HTR1D 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.